EGFR and non-small cell lung carcinoma: In line with the above-mentioned results of anti-PD1/PD-L1 immunotherapy in EGFR- or HER2-mutated stage IV NSCLC, a recent retrospective analysis of patients with unresectable stage III NSCLC treated with consolidation durvalumab after definitive chemoradiation reported a shorter PFS in the EGFR- or HER2-mutated NSCLC patients subgroup (7.5 mo vs. not reached, p = 0.04) [103].